Access
To read this story in full you will need to login or make a payment (see right).
Outlook
Nature 449, 164-165 (13 September 2007) | doi:10.1038/449164a; Published online 12 September 2007
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Senior Scientist, Cellular & Molecular Pharmacology
- Cortex Search Inc.
- Vancouver, British Columbia
Organic Chemistry
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
Neglected Diseases The path to new medicines
Bénédicte Callan1 & Iain Gillespie1
Abstract
Governments must help accelerate the development of drugs needed to treat infectious diseases in the developing world, say Bénédicte Callan and Iain Gillespie.
Over the next decade, it should be possible to produce a new generation of safe, effective and inexpensive medicines for many of the infectious diseases that afflict the poor. To achieve this, it will first be necessary to address the lack of viable commercial markets, to scale up the global capacity for research and development (R&D), and to build a more efficient and more open mechanism for the discovery of new drugs.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Human therapeutic proteins from silkwormsNature Biotechnology Research News (01 Jan 2003)
